Amoy Diagnostics, AstraZeneca team up to develop companion diagnostics programs
Roland Magnusson/iStock Editorial via Getty Images


China-based Amoy Diagnostics is collaborating with AstraZeneca (NASDAQ:AZN) to develop and sell AmoyDx assays that may cover any type of indication or biomarker for companion diagnostic (CDx) use with the British drugmaker's medicines globally.

A CDx is a test helps a health care professional determine whether a particular drug's benefits to patients will outweigh any potential serious side effects or risks and identify patients who are most likely to benefit from the particular medicine.
The first projects to be started include the co-development of a CDx to identify patients with prostate cancer with Homologous Recombination Repair gene mutations, in China, the EU and Japan; and a CDx to identify patients with breast cancer who have BRCA gene mutations, in the EU for Lynparza (olaparib) monotherapy.